This law firm has not supplied any contact details or supplementary information for this country or region. For more information about profiling options please contact Prin Shasiharan.
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China
Madeleine Kelly, the Australia-based IP firm’s new managing partner, discusses its new advisory offering, a promising fresh hire and changing market dynamics
It is a long-standing principle of Australian patent law that determining whether or not a patent application is directed towards patentable subject matter should be done separately to determining issues of novelty and inventive step.
The decision of the Full Federal Court in GlaxoSmithKline (GSK) Consumer Healthcare Investments (Ireland) (No 2) Limited v Generic Partners Pty Limited (2018) FCAFC 71 (May 10 2018) indicates that a mistake in a claim cannot be ignored even where the skilled person understands that a mistake has been made.
Beata Khaidurova and James Coburn of FB Rice delve into a chronology of Australian Patent Office decisions and find a pattern of reasoning which shows that some UIs may be protectable under Australian patent law
